New therapies for chronic hepatitis B infection
- 1 December 2006
- journal article
- Published by Wiley in Liver International
- Vol. 26 (S2) , 30-37
- https://doi.org/10.1111/j.1478-3231.2006.01373.x
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- 80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)Journal of Hepatology, 2006
- 519 Entecavir is superior to lamivudine for the treatment of chronic hepatitis B (CHB): Results of a phase 3 Chinese study (ETV-023) in nucleoside-naïve patientsJournal of Hepatology, 2006
- 45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)Journal of Hepatology, 2006
- A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis BGastroenterology, 2005
- 478 Entecavir (ETV) resistance is not observed in nucleoside-naive subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infectionJournal of Hepatology, 2005
- 95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudineJournal of Hepatology, 2004
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- New Treatment of Chronic Hepatitis BSeminars in Liver Disease, 2004
- Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis BHepatology, 2003